journal article·2021-12-14Open access

Tailored Nanoparticles as Vaccine Components

Alina Popa, Sebastian Springer

Applied Sciences· Volume 11· Issue 24

Abstract

Nanoparticles are components of many vaccines, helping to make them more stable and immunogenic. They protect antigens—or the genetic material encoding them—from degradation, target them to particular tissues or cells, promote their uptake into antigen-presenting cells, and activate the immune response (in the form of adjuvants). Nanoparticles come in many different kinds, some with uniform composition and some with elaborate core-and-shell structures, including lipid membranes. The antigen is usually retained inside, and the surface can be functionalized by targeting or activating proteins and carbohydrates. This minireview provides a general introductory overview to vaccination and a survey of nanoparticles, their types, production, characteristics, and individual applications in vaccines, and finally, a brief look into the world of artificial antigen-presenting cells.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · Hepatitis B Virus Studies · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Life Sciences and Chemistry, Jacobs University Bremen, 28759 Bremen, Germany

References (77)

Show source-provided references
1. The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2)10.1155/2021/8160860 ↗
2. Emerging Concepts and Technologies in Vaccine Development10.3389/fimmu.2020.583077 ↗
3. Synthetic Nanoparticles for Vaccines and Immunotherapy10.1021/acs.chemrev.5b00109 ↗
4. Junior Nanoparticle vaccines against viral infections10.1007/s00705-018-3856-0 ↗
5. Gomes, A.C., Mohsen, M., and Bachmann, M.F. (2017). Harnessing Nanoparticles for Immunomodulation and Vaccines. Vaccines, 5.10.3390/vaccines5010006 ↗
6. A Review of Mesoporous Silica Nanoparticle Delivery Systems in Chemo-Based Combination Cancer Therapies10.3389/fchem.2020.598722 ↗
7. Ho, J.K.-T., Jeevan-Raj, B., and Netter, H.-J. (2020). Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms. Viruses, 12.10.3390/v12020126 ↗
8. Polysaccharides-based nanoparticles as drug delivery systems10.1016/j.addr.2008.09.001 ↗
9. Human papillomavirus and HPV vaccines: A review10.2471/BLT.06.038414 ↗
10. Virus-like particle vaccines: Immunology and formulation for clinical translation10.1080/14760584.2018.1516552 ↗
11. Applications of silica-based nanoparticles for multimodal bioimaging10.1080/05704928.2017.1355312 ↗
12. Peptide-Based Vaccines: Current Progress and Future Challenges10.1021/acs.chemrev.9b00472 ↗
13. Self-assembling protein nanoparticles in the design of vaccines10.1016/j.csbj.2015.11.001 ↗
14. Souza, G., Rocha, R., Gonçalves, R., Ferreira, C., Silva, B., Castro, R., Rodrigues, J., Júnior, J., Malaquias, L., and Abrahão, J. (2021). Nanoparticles as Vaccines to Prevent Arbovirus Infection: A Long Road Ahead. Pathogens, 10.10.3390/pathogens10010036 ↗
15. Mechanisms of Action of Adjuvants10.3389/fimmu.2013.00114 ↗
16. Xiang, W., Liu, X., Zhang, L., Liu, C., and Liu, G. (2021). Cell membrane-encapsulated nanoparticles for vaccines and immunotherapy. Particuology, in press.10.1016/j.partic.2021.04.017 ↗
17. Distinct Immunologic Properties of Soluble Versus Particulate Antigens10.3389/fimmu.2018.00598 ↗
18. Recent advances in nano/microparticle-based oral vaccines10.1007/s40005-021-00537-9 ↗
19. Petkar, K., Patil, S., Chavhan, S., Kaneko, K., Sawant, K., Kunda, N., and Saleem, I. (2021). An Overview of Nanocarrier-Based Adjuvants for Vaccine Delivery. Pharmaceutics, 13.10.3390/pharmaceutics13040455 ↗
20. Chapter 4—Overview of the immune system10.1016/B978-0-444-63432-0.00004-9 ↗
21. Nanoparticles development for pulmonary vaccination: Challenges and opportunities
22. Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology10.1007/s40259-020-00419-w ↗
23. Immunological basis for enhanced immunity of nanoparticle vaccines10.1080/14760584.2019.1578216 ↗
24. Recent trends in vaccine delivery systems: A review10.4103/2230-973X.82384 ↗
25. Vaillant, A.A.J., and Grella, M.J. (2021, August 13). Vaccine (Vaccination), Available online: http://www.ncbi.nlm.nih.gov/books/NBK532895/.
26. Alfagih, I.M., Aldosari, B., AlQuadeib, B., Almurshedi, A., and Alfagih, M.M. (2020). Nanoparticles as Adjuvants and Nanodelivery Systems for mRNA-Based Vaccines. Pharmaceutics, 13.10.3390/pharmaceutics13010045 ↗
27. Fundamentals of Vaccine Immunology10.4103/0974-777X.77299 ↗
28. The contribution of vaccination to global health: Past, present and future10.1098/rstb.2013.0433 ↗
29. Subunit vaccines—Antigens, carriers, conjugation methods and the role of adjuvants10.5604/17322693.1077807 ↗
30. Conjugate vaccines and polysaccharide response10.1503/cmaj.1050269 ↗
31. Hepatitis B virus infection—Natural history and clinical consequences10.1056/NEJMra031087 ↗
32. Vaccine delivery using nanoparticles10.3389/fcimb.2013.00013 ↗
33. A Nanoparticle-Based Hepatitis C Virus Vaccine With Enhanced Potency
34. Nanoparticle Vaccines Against Infectious Diseases10.3389/fimmu.2018.02224 ↗
35. Nanoparticle vaccines10.1016/j.vaccine.2013.11.069 ↗
36. Engineering Targeting Materials for Therapeutic Cancer Vaccines10.3389/fbioe.2020.00019 ↗
37. Nanovaccines for cancer immunotherapy10.1002/wnan.1559 ↗
38. The history of MF59® adjuvant: A phoenix that arose from the ashes10.1586/erv.12.140 ↗
39. Montanide ISA 720 and 51: A new generation of water in oil emulsions as adjuvants for human vaccines10.1586/14760584.1.1.111 ↗
40. Receptor-specific delivery of protein antigen to dendritic cells by a nanoemulsion formed using top-down non-covalent click self-assembly10.1002/smll.201300078 ↗
41. Inflexal® V a trivalent virosome subunit influenza vaccine: Production10.1016/S0264-410X(02)00512-1 ↗
42. (2021, September 20). Epaxal: A Virosomal Vaccine to Prevent Hepatitis A Infection—PubMed, Available online: https://pubmed.ncbi.nlm.nih.gov/18844588/.
43. Polycation liposomes combined with calcium phosphate nanoparticles as a non-viral carrier for siRNA delivery10.1016/j.jddst.2015.09.005 ↗
44. Gold nanoparticles as a vaccine platform: Influence of size and shape on immunological responses in vitro and in vivo10.1021/nn3057005 ↗
45. Gold nanorod vaccine for respiratory syncytial virus10.1088/0957-4484/24/29/295102 ↗
46. Silica Nanoparticle as a Lymph Node Targeting Platform for Vaccine Delivery10.1021/acsami.7b06024 ↗
47. Bright and stable core-shell fluorescent silica nanoparticles10.1021/nl0482478 ↗
48. Recent advances in the rational design of silica-based nanoparticles for gene therapy10.4155/tde.12.98 ↗
49. Morato, Y.L., Paredes, K.O., Chamizo, L.L., Marciello, M., and Filice, M. (2021). Recent Advances in Multimodal Molecular Imaging of Cancer Mediated by Hybrid Magnetic Nanoparticles. Polymers, 13.10.3390/polym13172989 ↗
50. (2021, August 13). PLGA-Particle Vaccine Carrying TLR3/RIG-I Ligand Riboxxim Synergizes with Immune Checkpoint Blockade for Effective Anti-Cancer Immunotherapy|Nature Communications. Available online: https://www.nature.com/articles/s41467-021-23244-3.
51. Amphiphilic block copolymer delivery of a DNA vaccine against Zika virus10.1016/j.vaccine.2018.10.022 ↗
52. PLGA Nanoparticles Co-encapsulating NY-ESO-1 Peptides and IMM60 Induce Robust CD8 and CD4 T Cell and B Cell Responses10.3389/fimmu.2021.641703 ↗
53. Micelle-Based Adjuvants for Subunit Vaccine Delivery10.3390/vaccines3040803 ↗
54. Gutjahr, A., Phelip, C., Coolen, A.-L., Monge, C., Boisgard, A.-S., Paul, S., and Verrier, B. (2016). Biodegradable Polymeric Nanoparticles-Based Vaccine Adjuvants for Lymph Nodes Targeting. Vaccines, 4.10.3390/vaccines4040034 ↗
55. Zhao, L., Jin, W., Cruz, J.G., Marasini, N., Khalil, Z.G., Capon, R.J., Hussein, W.M., Skwarczynski, M., and Toth, I. (2020). Development of Polyelectrolyte Complexes for the Delivery of Peptide-Based Subunit Vaccines against Group A Streptococcus. Nanomaterials, 10.10.3390/nano10050823 ↗
56. Polyelectrolyte complexes as nanoparticulate drug delivery systems
57. Multifunctionalized polymer microcapsules: Novel tools for biological and pharmacological applications10.1002/smll.200600622 ↗
58. Multi-layer microcapsules: Fresh insights and new applications10.1080/17425247.2017.1285279 ↗
59. (2021, September 20). Protein A Functionalized Polyelectrolyte Microcapsules as a Universal Platform for Enhanced Targeting of Cell Surface Receptors|ACS Applied Materials & Interfaces. Available online: https://pubs.acs.org/doi/10.1021/acsami.7b01313.
60. Efficient oral vaccination by bioengineering virus-like particles with protozoan surface proteins10.1038/s41467-018-08265-9 ↗
61. Virus-Like Particle Vaccines Against Respiratory Viruses and Protozoan Parasites
62. Escherichia coli-derived virus-like particles in vaccine development10.1038/s41541-017-0006-8 ↗
63. Virus like particles production in green plants10.1016/j.ymeth.2006.05.020 ↗
64. HPV6b virus like particles are potent immunogens without adjuvant in man10.1016/S0264-410X(99)00351-5 ↗
65. RTS,S Clinical Trials Partnership (2015). Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: Final results of a phase 3, individually randomised, controlled trial. Lancet, 386, 31–45.10.1016/S0140-6736(15)60721-8 ↗
66. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine10.1016/0264-410X(90)90222-8 ↗
67. Landry, N., Ward, B.J., Trepanier, S., Montomoli, E., Dargis, M., Lapini, G., and Vézina, L.-P. (2010). Preclinical and Clinical Development of Plant-Made Virus-Like Particle Vaccine against Avian H5N1 Influenza. PLoS ONE, 5.10.1371/journal.pone.0015559 ↗
68. Establishment of a yeast-based VLP platform for antigen presentation10.1186/s12934-018-0868-0 ↗
69. Bacterial superglue enables easy development of efficient virus-like particle based vaccines10.1186/s12951-016-0181-1 ↗
70. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses10.1016/S0264-410X(02)00266-9 ↗
71. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses10.1038/s41467-020-20654-7 ↗
72. Design of a hyperstable 60-subunit protein icosahedron10.1038/nature18010 ↗
73. The Basics of Artificial Antigen Presenting Cells in T Cell-Based Cancer Immunotherapies
74. Towards efficient cancer immunotherapy: Advances in developing artificial antigen-presenting cells10.1016/j.tibtech.2014.06.007 ↗
75. Chapter Six—Engineering Platforms for T Cell Modulation10.1016/bs.ircmb.2018.06.003 ↗
76. Strategies to Use Nanoparticles to Generate CD4 and CD8 Regulatory T Cells for the Treatment of SLE and Other Autoimmune Diseases10.3389/fimmu.2021.681062 ↗
77. Mammalian retrovirus-like protein PEG10 packages its own mRNA and can be pseudotyped for mRNA delivery10.1126/science.abg6155 ↗